Maria Vittoria Dieci1, Vassilena Tsvetkova2, Gaia Griguolo1, Federica Miglietta3, Giulia Tasca4, Carlo Alberto Giorgi4, Enrico Cumerlato3, Davide Massa3, Marcello Lo Mele5, Enrico Orvieto6, Valentina Guarneri7, Pierfranco Conte1. 1. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy. 2. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Anatomy and Histology Unit, Padova Hospital, Padova, Italy. 3. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. 4. Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy. 5. Anatomy and Histology Unit, Padova Hospital, Padova, Italy. 6. Pathology Unit, Ulss 5 Polesana, Rovigo, Italy. 7. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy. Electronic address: valentina.guarneri@unipd.it.
Abstract
BACKGROUND: Tumour infiltrating lymphocytes (TILs) are an established prognostic biomarker for triple-negative breast cancer (TNBC). We evaluated the role of programmed cell-death ligand-1 (PD-L1), CD8 and FOXP3 expression in refining a prognostic model for non-metastatic TNBC beyond classic factors and TILs. METHODS: Primary tumour samples from 244 early patients with TNBC, all treated with surgery and chemotherapy, were collected. Stromal TILs were evaluated on haematoxylin-eosin slides according to guidelines. PD-L1, CD8 and FOXP3 were assessed by immunohistochemistry and evaluated by digital pathology. RESULTS: TILs, PD-L1, CD8 and FOXP3 were positively correlated with each other (P < 0.001). TILs were confirmed as an independent prognostic factor. When PD-L1, CD8 and FOXP3 were added to multivariable models including classic factors (age, stage, histologic grade) and TILs, PD-L1 provided the largest amount of additional prognostic information: likelihood ratio χ2 4.60, P = 0.032 (in a model including classic factors and TILs 10% increments) and likelihood ratio χ2 6.50, P = 0.011 (in a model including classic factors and TILs >30% versus <30%). In the subset of patients treated with neoadjuvant chemotherapy, FOXP3 provided further prognostic information beyond classic factors, TILs and pathological complete response (pCR) (likelihood ratio χ2 5.01, P = 0.025). For patients who did not achieve a pCR, the expression of CD8 and PD-L1 was significantly increased from baseline to residual disease. CONCLUSIONS: Beyond clinicopathological factors and TILs, other immune biomarkers may add prognostic information for early TNBC. The increased PD-L1 expression on residual disease after neoadjuvant chemotherapy strengthens the rationale of testing immune checkpoint inhibitors in the post-neoadjuvant setting.
BACKGROUND:Tumour infiltrating lymphocytes (TILs) are an established prognostic biomarker for triple-negative breast cancer (TNBC). We evaluated the role of programmed cell-death ligand-1 (PD-L1), CD8 and FOXP3 expression in refining a prognostic model for non-metastatic TNBC beyond classic factors and TILs. METHODS: Primary tumour samples from 244 early patients with TNBC, all treated with surgery and chemotherapy, were collected. Stromal TILs were evaluated on haematoxylin-eosin slides according to guidelines. PD-L1, CD8 and FOXP3 were assessed by immunohistochemistry and evaluated by digital pathology. RESULTS: TILs, PD-L1, CD8 and FOXP3 were positively correlated with each other (P < 0.001). TILs were confirmed as an independent prognostic factor. When PD-L1, CD8 and FOXP3 were added to multivariable models including classic factors (age, stage, histologic grade) and TILs, PD-L1 provided the largest amount of additional prognostic information: likelihood ratio χ2 4.60, P = 0.032 (in a model including classic factors and TILs 10% increments) and likelihood ratio χ2 6.50, P = 0.011 (in a model including classic factors and TILs >30% versus <30%). In the subset of patients treated with neoadjuvant chemotherapy, FOXP3 provided further prognostic information beyond classic factors, TILs and pathological complete response (pCR) (likelihood ratio χ2 5.01, P = 0.025). For patients who did not achieve a pCR, the expression of CD8 and PD-L1 was significantly increased from baseline to residual disease. CONCLUSIONS: Beyond clinicopathological factors and TILs, other immune biomarkers may add prognostic information for early TNBC. The increased PD-L1 expression on residual disease after neoadjuvant chemotherapy strengthens the rationale of testing immune checkpoint inhibitors in the post-neoadjuvant setting.
Authors: Marylène Lejeune; Benoît Plancoulaine; Nicolas Elie; Ramon Bosch; Laia Fontoura; Izar de Villasante; Anna Korzyńska; Andrea Gras Navarro; Esther Sauras Colón; Carlos López Journal: Histochem Cell Biol Date: 2021-08-12 Impact factor: 4.304
Authors: Victor Sarradin; Amélie Lusque; Thomas Filleron; Florence Dalenc; Camille Franchet Journal: Breast Cancer Res Date: 2021-05-26 Impact factor: 6.466
Authors: Davide Massa; Anna Tosi; Antonio Rosato; Valentina Guarneri; Maria Vittoria Dieci Journal: Cancers (Basel) Date: 2022-10-06 Impact factor: 6.575
Authors: Nanna Jørgensen; Thomas Vauvert F Hviid; Lise B Nielsen; Ida M H Sønderstrup; Jens Ole Eriksen; Bent Ejlertsen; Anne-Marie Gerdes; Torben A Kruse; Mads Thomassen; Maj-Britt Jensen; Anne-Vibeke Lænkholm Journal: Br J Cancer Date: 2021-08-07 Impact factor: 9.075
Authors: Serdar Altinay; Laurent Arnould; Maschenka Balkenhol; Glenn Broeckx; Octavio Burguès; Cecile Colpaert; Franceska Dedeurwaerdere; Benjamin Dessauvagie; Valérie Duwel; Giuseppe Floris; Stephen Fox; Clara Gerosa; Delfyne Hastir; Shabnam Jaffer; Eline Kurpershoek; Magali Lacroix-Triki; Andoni Laka; Kathleen Lambein; Gaëtan Marie MacGrogan; Caterina Marchiò; Maria-Dolores Martin Martinez; Sharon Nofech-Mozes; Dieter Peeters; Alberto Ravarino; Emily Reisenbichler; Erika Resetkova; Souzan Sanati; Anne-Marie Schelfhout; Vera Schelfhout; Abeer Shaaban; Renata Sinke; Claudia M Stanciu-Pop; Carolien H M van Deurzen; Koen K Van de Vijver; Anne-Sophie Van Rompuy; Anne Vincent-Salomon; Hannah Y Wen; Serena Wong; Mieke R Van Bockstal; Aline François; Caroline Bouzin; Christine Galant Journal: Mod Pathol Date: 2021-07-03 Impact factor: 7.842